Clinical trials: Behaviour
Smoking Cessation
Personalized Smoking Cessation Tool Based on Patient Lung CT Image
Imbio is developing a Smoking Cessation Report (Report) that includes data analysis from a CT lung cancer screening exam. This randomized controlled (RCT) trial will clinically validate the Report's effectiveness at motivating…
- Trial name
- NCT03087617
- Testing
- Imbio Smoking Cessation Report, Smoking Cessation Counseling, Usual Care
- Where
- United States
- Volunteers
- 321 people
- Sponsor
- Imbio
Glucose Metabolism Disorders, Health Behavior
Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects
When all the food we eat is digested, it will increase blood glucose. Two people can have different glucose blood levels to the same food and one reason can be bacteria live in our gut.
- Conditions
- Glucose Metabolism Disorders, Health Behavior, Diabetes, Metabolic Disease
- Trial name
- NCT06051318
- Testing
- Standardized breakfast A, Standardized breakfast B
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- BiomeHub Biotechnology Company
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD.
- Trial name
- NCT01986062
- Testing
- AR11
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Depression, Anxiety, Healthy
Voice Biomarkers Predictive of Depression and Anxiety
The objective of this study is to collect data to improve the sensitivity and specificity of Kintsugi Voice's (formerly KiVATM) predictions on audio files.
- Conditions
- Depression, Anxiety, Healthy, Mental Health Wellness 1
- Trial name
- NCT05455905
- Testing
- Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Hamilton Depression Rating Scale
- Where
- United States
- Volunteers
- 19,533 people
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Alzheimer Disease
Virtual Patient Behavioral Response Training for Family Caregivers
Our study is designed to help caregivers of someone with Alzheimer's Disease and related dementia to understand and deal with the difficult behaviors of a person with dementia.
- Trial name
- NCT04489303
- Testing
- Caring Response App, Traditional Educational/Resources Program
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Diabetes Mellitus, Type 2
Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
Participants will be randomly assigned to either a positive affect skills intervention or a psychoeducation control group and assessed with questionnaires before, during, and after the 8-week program, as well as at 3 months, 6…
- Trial name
- NCT04068805
- Testing
- Happify
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Happify Inc.
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Feeding Behavior, Nutrients Intakes
Nutri-Bébé 2022 A French National Survey on Feeding Practice and Nutrient Intakes of Children Under 3 Years of Age
The Nutri-Bébé 2022 survey is an observational cross-sectional study aiming to update food consumption, practices and nutrient intakes in children under 3 years of age in metropolitan France.
- Trial name
- NBB2022 (NCT05649527)
- Where
- France
- Volunteers
- 1,224 people
- Sponsor
- Secteur Français des Aliments de l'Enfance
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Disintegration, Healthy
Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
This study is to find out how different types of capsules or tablets containing EDP1815 move through the GI tract and release the drug after being swallowed.
- Trial name
- NCT05066373
- Testing
- EDP1815 capsule A, EDP1815 capsule B, EDP1815 tablet
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Smoking Cessation
Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers.
- Trial name
- NCT03432273
- Testing
- Nicotine lozenge
- Where
- South Africa
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Epilepsy
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets.
- Trial name
- NCT00870688
- Testing
- sodium valproate
- Volunteers
- 82 people
- Sponsor
- Desitin Arzneimittel GmbH
ADHD
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
- Trial name
- NCT04027361
- Testing
- Amphetamine Extended Release (ER) Tablet 20 mg
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tris Pharma, Inc.
ADHD
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
- Trial name
- NCT00784654
- Testing
- Lisdexamfetamine dimesylate (LDX)
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 276 people
- Sponsor
- Shire
Neurobehavioral Disinhibition
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury…
- Trial name
- NCT03095066
- Testing
- AVP-786-28, AVP-786-42.63
- Where
- 54 sites in United States
- Volunteers
- 168 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Health, Subjective, Gastrointestinal Dysfunction
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease…
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- LIFE-HOUSE (NCT04005456)
- Testing
- Supplements and/or medical foods, Behavioral change support program, Food plan
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Heart Failure，Congestive
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to…
- Trial name
- NCT03519477
- Testing
- Sano Patient Medication Profile
- Where
- United States
- Sponsor
- Precera Bioscience, Inc.
Nocturia
Daytime Impact Sleep Study
This trial will investigate the relationship of sleep, daytime performance and nocturia in patients treated with Desmopressin or placebo.
- Trial name
- DAISS (NCT01779466)
- Testing
- Desmopressin
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Ferring Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.